341 related articles for article (PubMed ID: 18505229)
1. Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.
Gesek FA; Desmond JS
Nephrol Nurs J; 2008; 35(2 Suppl):5S-22S; quiz 23S. PubMed ID: 18505229
[TBL] [Abstract][Full Text] [Related]
2. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
3. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
4. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
Mehrotra R
J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
[TBL] [Abstract][Full Text] [Related]
5. Mineral metabolism disturbances in patients with chronic kidney disease.
Kestenbaum B; Belozeroff V
Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
7. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
8. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D supplementation in CKD.
Martin KJ; González EA
Clin Nephrol; 2011 Apr; 75(4):286-93. PubMed ID: 21426882
[TBL] [Abstract][Full Text] [Related]
11. The dual vitamin D pathways: considerations for adequate supplementation.
Cronin SC
Nephrol Nurs J; 2010; 37(1):19-26, 36; quiz 27-8. PubMed ID: 20333900
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D treatment in chronic kidney disease.
Andress DL
Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
[TBL] [Abstract][Full Text] [Related]
13. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease.
Raggi P; Kleerekoper M
Clin J Am Soc Nephrol; 2008 May; 3(3):836-43. PubMed ID: 18322050
[TBL] [Abstract][Full Text] [Related]
14. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
Sprague SM; Coyne D
Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
[TBL] [Abstract][Full Text] [Related]
15. [Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
Sánchez González MC; Fernandez Giraldez E; Valdivielso Revilla JM
Nefrologia; 2008; 28 Suppl 5():39-45. PubMed ID: 18847419
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia.
Román-García P; Carrillo-López N; Cannata-Andía JB
J Ren Care; 2009 Mar; 35 Suppl 1():34-8. PubMed ID: 19222729
[TBL] [Abstract][Full Text] [Related]
17. The role of vitamin D in vascular calcification in chronic kidney disease.
Wolisi GO; Moe SM
Semin Dial; 2005; 18(4):307-14. PubMed ID: 16076354
[TBL] [Abstract][Full Text] [Related]
18. Role of vitamin d receptor activators in cardio-renal syndromes.
Cozzolino M; Bruschetta E; Stucchi A; Ronco C; Cusi D
Semin Nephrol; 2012 Jan; 32(1):63-9. PubMed ID: 22365164
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
Gutiérrez OM
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
[TBL] [Abstract][Full Text] [Related]
20. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
